• Pexidartinib (PLX3397): CSF1R Research Context

  2026-10-08

  Pexidartinib (PLX3397) is a selective CSF1R-directed research compound with applications in macrophage biology, cancer research and neuroimmune studies. A 2025 mouse study links acute alcohol exposure, microglial activation and hippocampal synaptic dysregulation, but it used minocycline rather than Pexidartinib. The findings therefore support a rationale for testing CSF1R-mediated signaling inhibition, not a demonstrated role for Pexidartinib in alcohol-related seizure susceptibility.

• MK0787 vs β-Lactam Antibiotics: 1982 Evidence

  2026-10-08

  This 1982 comparative study assessed N-formimidoyl thienamycin (MK0787) across 470 clinical isolates and positioned it against several recently developed β-lactam antibiotics. Its main contribution was evidence that MK0787 combined broad gram-negative activity, including activity against Pseudomonas and Acinetobacter, with bactericidal effects that appeared largely independent of β-lactamase production.

• Parathyroid hormone (1-34) (human): Evidence

  2026-10-07

  Parathyroid hormone (1-34) (human) is an N-terminal PTH (1-34) peptide fragment used to study PTH/PTHrP receptor signaling, calcium homeostasis, and bone metabolism. Product-reported receptor and animal data support biological activity, while a 2026 CKD valvular-calcification study provides disease context rather than direct validation of this product as a treatment.

• PTH (1-34) in Bone and CKD Calcification Research

  2026-10-07

  Parathyroid hormone (1-34) (human) is a biologically active N-terminal PTH fragment used conceptually in studies of receptor signaling, bone remodeling, calcium homeostasis, and kidney-related calcification. This overview compares supplier-reported biochemical activity with findings from a 2026 Biochemical Pharmacology study linking PTH-associated valvular calcification to endothelial-to-mesenchymal transition, Notch signaling, and Foxp1. The evidence supports mechanistic research relevance, but does not establish that a particular commercial fragment is clinically effective or that findings from CKD valve models translate directly to osteoporosis or human treatment.

• Nuclear mTORC1 Functions Revealed by TerminaTOR

  2026-10-06

  Zhong and colleagues introduce TerminaTOR, a genetically encodable inhibitor that enables mTORC1 perturbation at defined subcellular locations. Their findings distinguish lysosomal mTORC1 signaling from a nuclear role in regulating transcription of CCAAT motif-containing genes, providing a framework for interpreting spatially organized PI3K/Akt/mTOR signaling.

• Angiotensin II: From Mechanism to Translation

  2026-10-06

  Angiotensin II is more than a vasoconstrictive peptide: it is a translational probe linking GPCR signaling, oxidative stress, endothelial dysfunction, and vascular remodeling. This thought-leadership perspective examines how the octapeptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe can support mechanistically coherent cardiovascular research while keeping evidence boundaries clear.

• Actinomycin D in Transcription and Cancer Research

  2026-10-05

  Actinomycin D is a potent transcriptional inhibitor used to examine RNA synthesis, transcriptional stress, apoptosis induction, and cancer-cell biology. This overview distinguishes supplier-described applications from findings reported in a 2023 lung adenocarcinoma study, while assessing evidence strength, mechanistic interpretation, and applicability limits.

• ARCA Cy3 EGFP mRNA: Evidence and Limits

  2026-10-04

  ARCA Cy3 EGFP mRNA (5-moUTP) combines an EGFP reporter, Cy3 fluorescence, an ARCA cap structure, and 5-methoxyuridine modified mRNA. The product supports conceptual studies of mRNA delivery, localization, translation, and immune-response boundaries, but the supplied sources do not establish product-specific performance across delivery systems.

• Kif9 Controls Centriolar Satellite Positioning

  2026-10-02

  A 2025 Current Biology study identifies the plus-end-directed kinesin Kif9 as a spatial regulator of centriolar satellites during interphase. Loss of Kif9 drives satellites toward the centrosome, alters local proteolysis and centrosomal kinase abundance, and ultimately compromises centrosome maturation and chromosome segregation.

• Actinomycin D Workflows for ESCC RNA Studies

  2026-10-01

  Use Actinomycin D as a controlled transcriptional shutoff tool to connect ESCC phenotypes with RNA stability, transcriptional stress, and apoptosis induction. This guide translates the SORBS2/TIMP3 findings into practical dose, sampling, validation, and troubleshooting strategies.

• Parathyroid hormone (1-34) (human) Research

  2026-10-01

  Use this defined PTH (1-34) peptide fragment to connect receptor pharmacology with bone remodeling and spatially organized kidney models. The workflow combines dose-controlled signaling assays, osteoporosis model benchmarks, and hypothesis-driven kidney assembloid experiments while separating established evidence from proposed applications.

• Azilsartan medoxomil monopotassium Workflow Guide

  2026-09-30

  Build more reproducible AT1-receptor experiments with a DMSO-compatible workflow for Azilsartan medoxomil monopotassium, from cell-free binding assays to translational blood pressure studies. The guide emphasizes concentration control, washout design, exposure timing, and practical troubleshooting for TAK 491 research.

• Dual Luciferase Assay System: From Signal to Mechanism

  2026-09-30

  The Dual Luciferase Reporter Gene System converts promoter activity into a normalized, mechanistically interpretable signal. This guide connects firefly–Renilla assay design with the MYC2-LBD40/42-CRL3BPM4 defense circuit and explains how to avoid misleading conclusions in gene expression regulation studies.

• Ambroxol Targets Nav1.8, TRPV1, and TRPA1

  2026-09-29

  A 2025 Journal of Pain study used whole-cell patch clamp recordings to examine how ambroxol modulates human and rat Nav1.8, human TRPV1, and human TRPA1. The findings support species-dependent Nav1.8 inhibition and weaker, concentration-dependent TRP-channel modulation as possible components of topical analgesia, while emphasizing the limits of translating in vitro potency to clinical treatment.

• Aclacinomycin A and Persistent rDNA Stress

  2026-09-29

  Aclacinomycin A, also called Aclarubicin, is more than a cytotoxic anthracycline: it can serve as a mechanistic probe for topological stress, persistent DNA lesions, and apoptosis. This article connects its known pharmacology with rDNA damage and PML-nucleolar biology while distinguishing direct evidence from testable experimental hypotheses.

8556 records 1/571 page Next 12345 下5页 Last page